Effects of semaglutide on obstructive sleep apnea risk and outcomes in patients with obesity - PubMed
6 hours ago
- #sleep apnea
- #obesity
- #semaglutide
- Semaglutide reduces risk of new-onset obstructive sleep apnea (OSA) in individuals with obesity (HR: 0.62).
- Semaglutide lowers risk of adverse composite outcomes (all-cause mortality, MACE, MAKE) in people with obesity and existing OSA (HR: 0.72).
- Benefits include reductions in all-cause mortality (HR: 0.37), major adverse cardiovascular events (HR: 0.72), and major adverse kidney events (HR: 0.54).
- Study based on large retrospective cohort using TriNetX data with propensity score matching.
- Findings robust across subgroups and sensitivity analyses.